[A female chronic myeloid leukemia patient who gave birth after stopping imatinib intentionally but who maintained a major molecular response with interferon].
Gan To Kagaku Ryoho
; 42(4): 477-9, 2015 Apr.
Article
de Ja
| MEDLINE
| ID: mdl-25963696
ABSTRACT
Imatinib was administrated to a 38-year-old woman with chronic myeloid leukemia(CML). A major molecular response (MMR)(≤5 copies/0.5 µgRNA in Amp-CML detected using the transcription mediated amplification/hybridization protection assay(TMA/HPA)method)was achieved in 18 months. She maintained MMR for 10 months, and wished to become pregnant. Imatinib was stopped intentionally because she wished to plan a pregnancy, but we prescribed interferon alpha (IFN-a)due to the likelihood of the CML recurring after pregnancy. The nausea caused by IFN-a was improved by administrating it during the night, and she gave birth to a healthy baby by a normal delivery, whilst maintaining MMR. In this case, IFN-a treatment gave good clinical results, the patient's prognosis was improved, and she could maintain a good quality of life. We consider this to be an informative example of IFN-a therapy for CML during pregnancy.
Recherche sur Google
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Pipérazines
/
Pyrimidines
/
Benzamides
/
Leucémie myéloïde chronique BCR-ABL positive
/
Interféron alpha
/
Antinéoplasiques
Type d'étude:
Prognostic_studies
Aspects:
Patient_preference
Limites:
Adult
/
Female
/
Humans
/
Pregnancy
Langue:
Ja
Journal:
Gan To Kagaku Ryoho
Année:
2015
Type de document:
Article